Breast cancer drug Abraxane now available in New Zealand
Following approval from the local regulatory authority, women in New Zealand now have access to the breast cancer drug Abraxane (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy, via privately-held Australian drugmaker Specialised Therapeutics and will be distributed by Healthcare Logistics, based in Auckland.
The drug, which uses novel nanoparticle technology to deliver the chemotherapeutic agent to the tumor site, has been shown to prolong patient survival times with overall fewer side effects compared with traditional solvent-based chemotherapy treatments.
Abraxane was developed by US firm Abraxis BioScience, which was acquired by fellow USA-based Celgene last year for $58 billion in cash up front and a possible total of $2.9 billion dependent on various milestones (The Pharma Letter July 1, 2010).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze